Clinical Study Data Request Registered Users, Please Login

Find by:

Study ID:
Medicine:
Phase:

Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Phase 3 Study - Determine Efficacy and Safety of Two Doses of Retigabine (900mg/Day and 600mg/Day) Used as Adjunctive Therapy in Refractory Epilepsy Patients with Partial-Onset Seizures
retigabine, ezogabine
VRX-RET-E22-302
NCT00235755
Seizures
Phase 3
 
A follow-on study VRX-RET-E22-304 was conducted
March 2015

Powered by ideaPoint, Inc.